vs

Side-by-side financial comparison of NICOLET BANKSHARES INC (NIC) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

NICOLET BANKSHARES INC is the larger business by last-quarter revenue ($104.0M vs $70.6M, roughly 1.5× Viridian Therapeutics, Inc.\DE). NICOLET BANKSHARES INC runs the higher net margin — 38.8% vs -49.0%, a 87.8% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 12.5%). NICOLET BANKSHARES INC produced more free cash flow last quarter ($149.4M vs $-84.7M).

Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

NIC vs VRDN — Head-to-Head

Bigger by revenue
NIC
NIC
1.5× larger
NIC
$104.0M
$70.6M
VRDN
Growing faster (revenue YoY)
VRDN
VRDN
+81945.6% gap
VRDN
81958.1%
12.5%
NIC
Higher net margin
NIC
NIC
87.8% more per $
NIC
38.8%
-49.0%
VRDN
More free cash flow
NIC
NIC
$234.2M more FCF
NIC
$149.4M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
NIC
NIC
VRDN
VRDN
Revenue
$104.0M
$70.6M
Net Profit
$40.3M
$-34.6M
Gross Margin
Operating Margin
48.3%
-56.7%
Net Margin
38.8%
-49.0%
Revenue YoY
12.5%
81958.1%
Net Profit YoY
16.9%
54.9%
EPS (diluted)
$2.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NIC
NIC
VRDN
VRDN
Q4 25
$104.0M
Q3 25
$102.9M
$70.6M
Q2 25
$95.7M
Q1 25
$89.4M
Q4 24
$92.4M
Q3 24
$90.7M
Q2 24
$85.0M
Q1 24
$82.2M
Net Profit
NIC
NIC
VRDN
VRDN
Q4 25
$40.3M
Q3 25
$41.7M
$-34.6M
Q2 25
$36.0M
Q1 25
$32.6M
Q4 24
$34.5M
Q3 24
$32.5M
Q2 24
$29.3M
Q1 24
$27.8M
Operating Margin
NIC
NIC
VRDN
VRDN
Q4 25
48.3%
Q3 25
50.4%
-56.7%
Q2 25
46.8%
Q1 25
44.9%
Q4 24
46.8%
Q3 24
45.0%
Q2 24
43.3%
Q1 24
41.8%
Net Margin
NIC
NIC
VRDN
VRDN
Q4 25
38.8%
Q3 25
40.6%
-49.0%
Q2 25
37.6%
Q1 25
36.4%
Q4 24
37.3%
Q3 24
35.8%
Q2 24
34.5%
Q1 24
33.8%
EPS (diluted)
NIC
NIC
VRDN
VRDN
Q4 25
$2.63
Q3 25
$2.73
Q2 25
$2.34
Q1 25
$2.08
Q4 24
$2.21
Q3 24
$2.10
Q2 24
$1.92
Q1 24
$1.82

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NIC
NIC
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$490.9M
Total DebtLower is stronger
$134.9M
Stockholders' EquityBook value
$1.3B
$503.0M
Total Assets
$9.2B
$577.1M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NIC
NIC
VRDN
VRDN
Q4 25
Q3 25
$490.9M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Total Debt
NIC
NIC
VRDN
VRDN
Q4 25
$134.9M
Q3 25
$134.6M
Q2 25
$134.3M
Q1 25
$156.6M
Q4 24
$161.4M
Q3 24
$161.2M
Q2 24
$162.4M
Q1 24
$162.3M
Stockholders' Equity
NIC
NIC
VRDN
VRDN
Q4 25
$1.3B
Q3 25
$1.2B
$503.0M
Q2 25
$1.2B
Q1 25
$1.2B
Q4 24
$1.2B
Q3 24
$1.1B
Q2 24
$1.1B
Q1 24
$1.1B
Total Assets
NIC
NIC
VRDN
VRDN
Q4 25
$9.2B
Q3 25
$9.0B
$577.1M
Q2 25
$8.9B
Q1 25
$9.0B
Q4 24
$8.8B
Q3 24
$8.6B
Q2 24
$8.6B
Q1 24
$8.4B
Debt / Equity
NIC
NIC
VRDN
VRDN
Q4 25
0.11×
Q3 25
0.11×
Q2 25
0.11×
Q1 25
0.13×
Q4 24
0.14×
Q3 24
0.14×
Q2 24
0.15×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NIC
NIC
VRDN
VRDN
Operating Cash FlowLast quarter
$153.5M
$-84.6M
Free Cash FlowOCF − Capex
$149.4M
$-84.7M
FCF MarginFCF / Revenue
143.7%
-120.1%
Capex IntensityCapex / Revenue
3.9%
0.2%
Cash ConversionOCF / Net Profit
3.81×
TTM Free Cash FlowTrailing 4 quarters
$275.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NIC
NIC
VRDN
VRDN
Q4 25
$153.5M
Q3 25
$45.9M
$-84.6M
Q2 25
$38.9M
Q1 25
$41.8M
Q4 24
$133.7M
Q3 24
$39.6M
Q2 24
$37.3M
Q1 24
$23.4M
Free Cash Flow
NIC
NIC
VRDN
VRDN
Q4 25
$149.4M
Q3 25
$45.9M
$-84.7M
Q2 25
$38.4M
Q1 25
$41.3M
Q4 24
$116.8M
Q3 24
$34.7M
Q2 24
$34.4M
Q1 24
$20.1M
FCF Margin
NIC
NIC
VRDN
VRDN
Q4 25
143.7%
Q3 25
44.6%
-120.1%
Q2 25
40.1%
Q1 25
46.2%
Q4 24
126.4%
Q3 24
38.3%
Q2 24
40.5%
Q1 24
24.4%
Capex Intensity
NIC
NIC
VRDN
VRDN
Q4 25
3.9%
Q3 25
0.0%
0.2%
Q2 25
0.6%
Q1 25
0.5%
Q4 24
18.3%
Q3 24
5.4%
Q2 24
3.5%
Q1 24
4.0%
Cash Conversion
NIC
NIC
VRDN
VRDN
Q4 25
3.81×
Q3 25
1.10×
Q2 25
1.08×
Q1 25
1.28×
Q4 24
3.88×
Q3 24
1.22×
Q2 24
1.28×
Q1 24
0.84×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons